Jean Jacques Bienaime Sells 20,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 20,000 shares of the business’s stock in a transaction on Friday, December 29th. The stock was sold at an average price of $89.75, for a total value of $1,795,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jean Jacques Bienaime also recently made the following trade(s):
- On Saturday, December 29th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $89.61, for a total value of $896,100.00.
BioMarin Pharmaceutical Inc. (BMRN) opened at $92.08 on Thursday. The company has a market capitalization of $16,170.00, a price-to-earnings ratio of -110.94 and a beta of 1.81. BioMarin Pharmaceutical Inc. has a 12 month low of $80.10 and a 12 month high of $100.51. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.
BMRN has been the topic of a number of research analyst reports. Goldman Sachs Group reiterated a “buy” rating and set a $129.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Jefferies Group reiterated a “buy” rating and set a $116.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 26th. Piper Jaffray Companies reiterated a “buy” rating and set a $113.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, September 21st. BMO Capital Markets reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Friday, September 15th. Finally, Stifel Nicolaus decreased their target price on BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating on the stock in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $112.44.
Institutional investors have recently added to or reduced their stakes in the stock. Toronto Dominion Bank increased its stake in BioMarin Pharmaceutical by 12.9% in the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 243 shares during the last quarter. Commerce Bank acquired a new stake in BioMarin Pharmaceutical during the third quarter worth about $209,000. Cambridge Investment Research Advisors Inc. acquired a new stake in BioMarin Pharmaceutical during the second quarter worth about $213,000. Teacher Retirement System of Texas acquired a new stake in BioMarin Pharmaceutical during the third quarter worth about $220,000. Finally, First Republic Investment Management Inc. acquired a new stake in BioMarin Pharmaceutical during the third quarter worth about $220,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.mareainformativa.com/2018/01/04/jean-jacques-bienaime-sells-20000-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.